胰高血糖素样肽-1受体激动剂不增加2型糖尿病患者急性胰腺炎风险且与急性胰腺炎并发症更低相关:一项多中心分析
一项基于TriNetX平台的多中心回顾性队列研究,纳入2型糖尿病患者,按1:1倾向性匹配比较使用与未使用胰高血糖素样肽-1受体激动剂(GLP-1 RAs)者。结果显示GLP-1 RAs不增加急性胰腺炎风险,且在发生急性胰腺炎者中与并发症和全因死亡率降低相关。
要点
- GLP-1 RAs使用不增加2型糖尿病患者急性胰腺炎风险。
- 发生急性胰腺炎时,GLP-1 RAs组并发症风险和全因死亡率更低。
- 非复杂性胰腺炎风险有降低趋势但未达统计学显著。
核心结论
- GLP-1 RAs使用不增加急性胰腺炎风险,且在发生急性胰腺炎者中与并发症更低相关,并与全因死亡率降低相关。
- 作者指出需要前瞻性研究来确定这些发现背后的机制。
研究设计与样本
- 采用TriNetX平台人群数据的回顾性队列研究。
- 纳入2015年1月1日至2023年10月31日期间接受GLP-1 RAs(司美格鲁肽、利拉鲁肽、度拉糖肽和替尔泊肽)的2型糖尿病患者。
- 按年龄、人口学、合并症和药物以1:1倾向性匹配与未接受GLP-1 RAs的2型糖尿病患者比较。
- 两队列均排除酒精性、创伤、胆源性、Ia类药物诱导、高甘油三酯血症及内镜逆行胰胆管造影后等病因的急性胰腺炎。
- 共识别740,370例2型糖尿病患者,其中29,423例使用GLP-1 RAs;29,423例中20,459例(平均[SD]年龄58.1[11.9]岁;10,190例[49.85%]女性)与20,459例未使用GLP-1 RAs者(平均[SD]年龄57.5[13.9]岁;10,301例[50.35%]女性)匹配。
主要发现
- 与未使用GLP-1 RAs组相比,GLP-1 RAs组复杂性胰腺炎风险更低(HR 0.32;95%CI 0.14-0.74)。
- 与未使用GLP-1 RAs组相比,GLP-1 RAs组需要肠外营养的风险更低(HR 0.28;95%CI 0.09-0.83)。
- 与未使用GLP-1 RAs组相比,GLP-1 RAs组脓毒症风险更低(HR 0.71;95%CI 0.59-0.84),急性肾损伤风险更低(HR 0.54;95%CI 0.49-0.60),休克风险更低(HR 0.52;95%CI 0.36-0.75),住院期间机械通气支持风险更低(HR 0.23;95%CI 0.16-0.33)。
- 与未使用GLP-1 RAs组相比,GLP-1 RAs组全因死亡率降低(HR 0.45;95%CI 0.41-0.49)。
- GLP-1 RAs组非复杂性胰腺炎风险有降低趋势(HR 0.71;95%CI 0.49-1.01),但未达统计学显著;两组发生全身炎症反应综合征的风险无差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出需要前瞻性研究来确定这些发现背后的机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Type 2 diabetes mellitus (T2DM) can lead to structural pancreatic changes potentially predisposing to acute pancreatitis (AP), increasing morbidity and mortality. Scarce data exist on the outcomes of AP in patients with T2DM who are taking glucagon-like peptide-1 receptor agonists (GLP-1 RAs). The study aim was to evaluate AP outcome and all-cause mortality in patients with T2DM using GLP-1 RAs. METHODS: A retrospective cohort study was performed using population-based data from the TriNetX platform. Patients with T2DM receiving GLP-1 RAs drugs (semaglutide, liraglutide, dulaglutide, and tirzepatide) between January 1, 2015, and October 31, 2023, were included. This patient cohort was matched with patients with T2DM who did not receive GLP-1 RAs according to age, demographics, comorbidities, and medication by using 1:1 propensity matching. To avoid confounding, etiologies of AP including alcohol-induced, trauma, biliary, class Ia drug-induced, hypertriglyceridemia, and postendoscopic retrograde cholangiopancreatography were excluded from both cohorts. Primary outcomes were risk of developing AP, need for parenteral nutrition, systemic complications (sepsis, systemic inflammatory response syndrome, shock, mechanical ventilation, acute kidney injury), and local pancreatic complications. The secondary outcome was all-cause mortality. Cox proportional hazards models were used to estimate hazard ratios (HRs). RESULTS: A total of 740,370 patients with T2DM were identified with 29,423 on GLP-1 RAs; 20,459 of those 29,423 (mean [SD] age, 58.1 [11.9] years; 10,190 [49.85%] female) were matched with 20,459 individuals (mean [SD] age, 57.5 [13.9] years; 10,301 [50.35%] female) who did not take GLP-1 RAs. The GLP-1 RAs group had lower risk of complicated pancreatitis (HR 0.32; 95% confidence interval [CI] 0.14-0.74), parenteral nutrition needs (HR 0.28; 95% CI 0.09-0.83), sepsis (HR 0.71; 95% CI 0.59-0.84), acute kidney injury (HR 0.54; 95% CI 0.49-0.60), shock (HR 0.52; 95% CI 0.36-0.75), and mechanical ventilation support during admission (HR 0.23; 95% CI 0.16-0.33) compared with the non-GLP-1 RAs group. In addition, all-cause mortality was decreased in the GLP-1 agonist group compared with the non-GLP-1 agonist group (HR 0.45; 95% CI 0.41-0.49). Important to note that the GLP-1 RAs group had a tendency of lower risk of uncomplicated pancreatitis (HR 0.71; 95% CI 0.49-1.01) but without statistically significant result. No difference was found between the groups in risk of developing systemic inflammatory response syndrome if it occurs. DISCUSSION: GLP-1 RAs use does not increase AP risk is associated with lower complications in those who developed AP and linked with lower all-cause mortality in patients with T2DM. Prospective studies are needed to determine the mechanisms behind these findings.
引用
- Nieto LM, Martinez J, Narvaez SI, et al. Glucagon-Like Peptide-1 Receptor Agonists Use Does Not Increase the Risk for Acute Pancreatitis and Is Associated With Lower Complications in Patients With Type 2 Diabetes Who Develop Acute Pancreatitis: A Multicenter Analysis. Am J Gastroenterol. 2025. PMID: 40358430. doi:10.14309/ajg.0000000000003525
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。